Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory proteins are influenced by acetylation. Inhibition of histone deacetylase (HDAC) prompts tumour cells to enter apoptosis and, as a consequence, several HDAC inhibitors have entered clinical trials. It is likely that HDAC inhibitor drugs will provide an important class of new mechanism-based therapeutics for cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.coph.2006.03.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer.
Adv Sci (Weinh)
January 2025
Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine; National Experimental Teaching Center of Basic Medical Science, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China.
Colorectal cancer (CRC) is highly resistant to ferroptosis, which hinders the application of anti-ferroptosis therapy. Through drug screening, it is found that histone deacetylase inhibitor (HDACi) significantly sensitized CRC to ferroptosis. The combination of HDACi and ferroptosis inducers synergically suppresses CRC growth both in vivo and in vitro.
View Article and Find Full Text PDFNuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.
Adv Sci (Weinh)
January 2025
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060.
Immunotherapy has gained approval for use in small cell lung cancer (SCLC), yet only a subset of patients (10-20%) experience meaningful benefits, underscoring the urgent need for more effective therapeutic approaches. This work discovers a distinct HDAC7-high SCLC phenotype characterized by enhanced proliferative potential, which recurs across various subtypes and serves as a predictor of poorer survival outcomes. By analyzing public datasets, this work finds a strong correlation between c-Myc and HDAC7.
View Article and Find Full Text PDFAmeliorative effects of root and rhizome extract on high fat diet‑induced obesity in mice through regulation of the SIRT1/PGC1α/AMPK pathways in muscle and liver tissues.
Mol Med Rep
March 2025
Department of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, Gyeongsangbuk 38066, Republic of Korea.
Asiasarum root and rhizome () is commonly used as a diaphoretic. Due to its warm and pungent characteristics in traditional Chinese and Korean medicine, it is considered as having the potential to prevent disease. The present study investigated the effects of extract on the symptoms of obesity in mice, and the regulation of energy metabolism in the liver and skeletal muscle tissues.
View Article and Find Full Text PDFAnticancer activity of , a rare and endemic species of holly in Northeast India, against murine lymphoma.
Heliyon
January 2025
DBT-BUILDER National Laboratory, Department of Life Sciences, Pachhunga University College, Aizawl, 796001, Mizoram, India.
Purkay. is a lesser-known species of holly (family Aquifoliaceae) that is endemic to Northeast India. Designated as critically endangered, the plant is used in the treatments of bacterial infections, cancer, intestinal helminthiasis, tuberculosis, and viral infections.
View Article and Find Full Text PDFPioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents.
Future Med Chem
January 2025
Department of Organic Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Aim: With the aim of simultaneously modulating the epigenetic system and the protein kinase pathway, we selected the enzyme histone deacetylase (HDAC) and the Rho-associated protein kinases (ROCK) as desired targets to develop potential multitarget anticancer agents with additional antimetastatic properties. We report here the rational design, synthesis, and biological evaluation of the HDAC/ROCK multitarget inhibitors in pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC).
Materials And Methods: A molecular docking study performed with the Gold software was used to develop HDAC/ROCK multitarget inhibitors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!